Cellectis S.A. fell 12.0% on Thursday, November 5, 2026, on 84,544 shares. Headlines around the move:
Cellectis S.A. (CLLS:NASDAQ) closed at $1.07 on November 6, 2026, up 3.88% on the day. The stock trades 80.4% below its 52-week high of $5.45 and 21.5% above its 52-week low of $0.881. Over the past year, it lost 66.5%. Cellectis S.A. is part of the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)).
In 252 trading sessions since November 6, 2025, CLLS closed higher on 112 days (44%). Its best day was October 28, 2026 (+20.00%) and its worst was September 14, 2026 (-40.97%). The stock moved 10% or more in a single session 14 times. It opened at least 5% above the previous day's high 7 times.
Cellectis SA is a gene-editing company, employing its core proprietary technologies to develop products in the emerging field of immuno-oncology. Its two segment includes Therapeutics and Plants.
Find more stocks like CLLS with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.